The Origin of AIDS
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Guide to Preparing Multiple Choice Items
A Guide to Preparing Multiple Choice Items Introduction The most commonly used type of test item in admissions, certification, and licensure examinations is the multiple choice item. The purpose of this guide is to assist test developers and representatives of professional associations in becoming more skilled in writing multiple choice test items. Preparing multiple choice items may appear on the surface to be a relatively simple task, given familiarity with the subject matter. However, experienced test authors find that this task actually requires a great deal of skill, patience, and creativity. In the sections that follow, general knowledge is used as the content of the examples, in order to facilitate understanding of the principles by professionals from diverse content areas. The skills needed for writing quality items are similar regardless of content discipline. Like any other skill, multiple choice item writing requires a significant amount of painstaking practice with appropriate feedback. It is essential that you try out your multiple choice items on others. This process will help you to uncover ambiguities in wording and unintended violations of item writing principles. Feedback from others will greatly enhance your item writing quality and productivity. Parts of the Multiple Choice Item All multiple choice items consist of two basic parts: the stem and the responses. The stem is the introductory statement or question that elicits the correct answer. The responses are suggested answers which complete the statement or answer the question asked in the stem, only one of which is the correct answer. In the examples that follow, four responses (i.e., 1 correct response and 3 incorrect responses) are presented. -
Jonas Salk at the National Press Club, April 12, 1965
Jonas Salk at the National Press Club, April 12, 1965 Jonas Salk, May 1962. A.F.P. – D.P.A. Photos. National Press Club Archives On the tenth anniversary of the licensing of the polio vaccine he developed, Dr. Jonas E. Salk (1914-1995) visited Washington to accept a joint congressional resolution that hailed the vaccine as “one of the most significant medical achievements of our time.” At the White House, President Johnson offered Salk his congratulations. The day also marked the twentieth anniversary of the death of former President Franklin D. Roosevelt, who, having suffered from paralytic polio since 1921, had established the foundation that funded Salk’s efforts. Following his meetings with Congress and the President, Salk gave a talk and answered reporters’ questions at a National Press Club luncheon. In the title of its lead editorial ten years earlier celebrating the successful testing of the new vaccine, the New York Times proclaimed the “Dawn of a New Medical Day.” Testing of the vaccine, like the funding for its development, had engaged the participation of millions of ordinary American citizens. Through March of Dimes campaigns, hundreds of thousands of volunteers went door-to-door raising $41 million in 1952 alone from average donations of 27 cents. The tests involved 1.8 million school children, 200,000 volunteers, 64,000 teachers, and 60,000 physicians, nurses, and health officials, making it the largest clinical trial in history. Interpreting the jubilant 1 reaction to news that the vaccine had been proven safe and effective, the Times commented, “Gone are the old helplessness, the fear of an invisible enemy, the frustration of physicians.” Poliomyelitis, also known as infantile paralysis, is an extremely contagious viral infection caused by any of three types of poliovirus. -
Poliomyelitis in the Lone Star State
POLIOMYELITIS IN THE LONE STAR STATE: A BRIEF EXAMINATION IN RURAL AND URBAN COMMUNITIES THESIS Presented to the Graduate Council of Texas State University in Partial Fulfillment of the Requirements For the Degree Master of Arts By Jason C. Lee San Marcos, Texas December, 2005 Insert signature page here ii COPYRIGHT By Jason Chu Lee 2005 iii ACKNOWLEDGEMENTS It leaves me in a stupor to contemplate all those I have to thank for aiding me in this effort. If I leave anybody out, please accept my most humble apologies, as the list is long. I will be the first to admit that this work is flawed, despite the best efforts of my committee to save me from myself. Had I utilized them more, this piece would only be improved. I had never undertaken a project of this scope before and though I believe I have accomplished much, the experience has been humbling. Never again will I utter the phrase, “just a thesis.” My biggest thanks go out to Dr. Mary Brennan, my committee chair and mentor. Without her guidance I most certainly would have needed to take comprehensive finals to graduate. She helped me salvage weeks of research that I thought had no discernable use. But Dr. Brennan, despite her very, very busy schedule with the department and her family, still found the time to help me find my thesis in all the data. She is well loved in the department for obvious reasons, as she has a gift for being firm and professional while remaining compassionate. Dr. James Wilson and Dr. -
Vaccine Symposium Louis Pasteur As Pioneers Who Fundamentally Changed the Nature of Presented by the MSU Department of Microbiology & Immunology Human Health
Maurice Hilleman, 1919-2005, was a 1941 MSU graduate who saved the lives of millions by developing a wide array of vaccines. nd 2 Maurice Hilleman A Miles City native, Hilleman graduated atop his class at what was then Montana State College with dual degrees in chemistry and microbiology. His name often accompanies those of Jonas Salk and Vaccine Symposium Louis Pasteur as pioneers who fundamentally changed the nature of Presented by the MSU Department of Microbiology & Immunology human health. The abstract on a National Institutes of Health obituary for Hilleman describes him this way: "Microbe hunter, pioneering virologist, and the world's leading vaccinologist." Mi Among Hilleman's scientific achievements: • A hepatitis B vaccine that was the first vaccine to prevent a cancer in humans (liver cancer, or hepatoma). • A measles-mumps-and-rubella combination vaccine chat marked the first time vaccines for different viruses were successfully combined in a single shot. • Vaccines for meningitis and pneumonia. • A mumps vaccine that came after Hilleman isolated the virus by swabbing the back of his daughter Jeryl Lynn's throat when she was stricken with the disease (50 years later it is still the basis for most mumps vaccines). • A more complete understanding of the ways different strains of the flu change slightly from year to year, which led to the practice of developing an annual seasonal flu vaccine. • The first successful prediction of a coming influenza pandemic and development of a vaccine that thwarted it, 2018 possibly saving close to a million people in 1957. Indeed, Hilleman was responsible for developing 8 out of the 14 recommended vaccinations today. -
Re-Thinking Pandemics: State, Society, and Disease in British History, 1830-1960
Providence College DigitalCommons@Providence History & Classics Undergraduate Theses History & Classics Spring 2021 Re-thinking Pandemics: State, Society, and Disease in British History, 1830-1960 Meghan Walsh Follow this and additional works at: https://digitalcommons.providence.edu/history_undergrad_theses Part of the European History Commons, and the History of Science, Technology, and Medicine Commons Re-thinking Pandemics: State, Society, and Disease in British History, 1830-1960 by Meghan Walsh HIS 490 History Honors Thesis Department of History and Classics Providence College Spring 2021 This thesis is dedicated to the 3 million people who lost their lives to COVID-19 and to all the frontline workers and essential employees, without whom nothing would be possible. “Epidemics all follow this similar arc where people deny or dismiss the threat until it becomes impossible to ignore any more,” - Mark Honigsbaum, medical historian at City, University of London CONTENTS ACKNOWLEDGEMENTS………………………………………………………………………vi INTRODUCTION …………………………………………...……………………………………1 CHAPTER 1: THE STORY OF CHOLERA ……………………………………………………..8 CHAPTER 2: IGNORING INFLUENZA………………………………………………………..23 CHAPTER 3: TREATING POLIO ……………………………………………………………...36 CONCLUSION: HOW THINGS HAVE CHANGED…………………………………………...54 BIBLIOGRAPHY.........………………………………………………………………………….59 v ACKNOWLEDGEMENTS A project this size truly takes a village, and I am eternally grateful to mine for seeing me through to the end of this. Researching and immersing myself in the lives and experiences of British citizens from three major pandemics, whilst living in one, was an interesting journey, but several people ensured I never went on it alone. To Dr. Smith and Dr. Murphy, thank you for making this possible and for granting me the opportunity to write a senior thesis. Your comments, guidance and encouragement were invaluable. -
The March of Dimes and Polio: Lessons in Vaccine Advocacy for Health Educators
Feature Article The March of Dimes and Polio: Lessons in Vaccine Advocacy for Health Educators Dawn Larsen ABSTRACT The polio vaccine became available in 1955, due almost entirely to the efforts of the March of Dimes. In 1921, Franklin Roosevelt gave a public face to polio and mounted a campaign to prevent it, establishing the National Foundation for Infantile Paralysis in 1938. During the Depression, U.S. citizens were asked to contribute one dime. Entertainer Eddie Cantor suggested the name the March of Dimes, paraphrasing the popular newsreel “The March of Time.” Jonas Salk advocated a killed-virus vaccine while Albert Sabin proposed a live-virus vaccine. Both competed for both recognition and funding from the March of Dimes. In 1955 Salk’s vaccine was adopted, nationwide vaccination programs were implemented, and polio rates dropped by 80 percent. In 1961, Sabin’s vaccine, endorsed by the American Medical Association, became the vaccine of choice. The World Health Assembly advocated polio eradication by the year 2000. By 2004 eradication efforts were threatened by allegations linking vaccines to chronic diseases. Immunization dropped and polio resurfaced in the U.S., Australia, Africa and Russia. Research linking vaccines to chronic disease was dis- credited, but vaccine opponents remain active. Health educators are well positioned to mitigate damage caused by the anti-vaccine movement and address barriers to immunization efforts. Larsen D. The March of Dimes and polio: lessons in vaccine advocacy for health educators. Am J Health Educ. 2012;43(1):47-54. Submitted May 30, 2011. Accepted July 9, 2011. In 2008, The March of Dimes cel- prenatal health promotion programs, and of the virus that has been ranked second ebrated its 70th anniversary. -
INFLUENZA VIRUS VACCINE THREE YEARS EXPERIENCE in the U. 8. ARMY by LT. COL. T. G. FAISON Ojke of the Surgeon General, Washingto
INFLUENZA VIRUS VACCINE THREE YEARS EXPERIENCE IN THE U. 8. ARMY By LT. COL.T. G. FAISON Ojke of the Surgeon General, Washington, D. C. It is a pleasure and privilege to be able to meet with the United States- Mexico Border Public Health Association. Rapid transportation has increased the need for cooperative action in the field of national and international health. The vectors and agents of disease do not respect international boundaries or treaties. 1 have always been impressed by the amicable international relation- ship between doctors, other scientific men and especially public health personnel. The results of this friendly and cooperative attitude have been most beneficial to mankmd. For the three year period 1945 to 1948, the U. S. Army required the inoculation of al1 troops with influenza virus vaccine. The vaccine con- tained 50% Type B (Lee), 25% Type A PR8, and 25% A Prime (Weiss or FMl) strains. The decision to vaccinate was based largely upon the signifkant results obtained in evaluation studies of influenza virus vaccine during 1943 and 1945** 2, 3. Since 1945, evaluation studies con- ducted by the Commission on Influenza of the Army Epidemiological Board and other investigators have not been in satisfactory agreement as to results which would determine the advisability of its use4* 6* 6* l. In 1946-1947 and again in 1947-1948, reports show that the influenza vaccine which was given afforded no protection against the type of in- l Francis, Thomas; Jonas Salk; and William M. Brace: The Protective Effect of Vaccination Against Epidemic Influenza B, Jour. -
Poliomyelitis and the Salk Vaccine
Poliomyelitis and the Salk Vaccine Table of Contents Preface......................................................................................................................................................................................................... 2 Center for the History of Medicine ......................................................................................................................................................... 2 Introduction ................................................................................................................................................................................................. 3 Collections .................................................................................................................................................................................................. 5 1 Return to Table of Contents Preface The Bentley Historical Library and the Historical Center for the Health Sciences (now the Center for the History of Medicine), with support from the Southeast Michigan Chapter of the March of Dimes Birth Defects Foundation, collaborated to commemorate the 40th anniversary of the announcement that the poliomyelitis vaccine developed by Dr. Jonas Salk was safe and effective. As part of the commemoration, a printed guide was prepared to highlight and illustrate the archival and manuscript holdings in the Bentley Historical Library relating to polio and the development and the testing of the Salk vaccine. In the period since the guide was published, -
A Truncated Nef Peptide from Sivcpz Inhibits the Production of HIV-1 Infectious Progeny
viruses Article A Truncated Nef Peptide from SIVcpz Inhibits the Production of HIV-1 Infectious Progeny Marcela Sabino Cunha 1,†, Thatiane Lima Sampaio 1,†, B. Matija Peterlin 2 and Luciana Jesus da Costa 1,* 1 Departamento de Virologia—Instituto de Microbiologia, Universidade Federal do Rio de Janeiro, Av. Carlos Chagas Filho 373—CCS—Bloco I, Rio de Janeiro 21941-902, Brazil; [email protected] (M.S.C.); [email protected] (T.L.S.) 2 Departments of Medicine, Microbiology and Immunology, University of California, San Francisco, 533 Parnassus Avenue, San Francisco, CA 94143, USA; [email protected] * Correspondence: [email protected]; Tel.: +55-21-2560-8344 (ext. 117); Fax: +55-21-2560-8344 † These authors contributed equally to this work. Academic Editor: Andrew Mehle Received: 29 February 2016; Accepted: 14 June 2016; Published: 7 July 2016 Abstract: Nef proteins from all primate Lentiviruses, including the simian immunodeficiency virus of chimpanzees (SIVcpz), increase viral progeny infectivity. However, the function of Nef involved with the increase in viral infectivity is still not completely understood. Nonetheless, until now, studies investigating the functions of Nef from SIVcpz have been conducted in the context of the HIV-1 proviruses. In an attempt to investigate the role played by Nef during the replication cycle of an SIVcpz, a Nef-defective derivative was obtained from the SIVcpzWTGab2 clone by introducing a frame shift mutation at a unique restriction site within the nef sequence. This nef -deleted clone expresses an N-terminal 74-amino acid truncated peptide of Nef and was named SIVcpz-tNef. We found that the SIVcpz-tNef does not behave as a classic nef -deleted HIV-1 or simian immunodeficiency virus of macaques SIVmac. -
The 1954 Field Trial of the Salk Poliomyelitis Vaccine Paul Meier University of Chicago
TIIE BIGGEST PUBLIC IIEALTH EXPERIMENT EVER: The 1954 Field Trial of the Salk Poliomyelitis Vaccine Paul Meier University of Chicago [ Chapter 2 in Tanur JM et al. (Editors) Statistics: A Guide to the Unknown. Holden-Day San Francisco 1972 ] THE LARGEST and most expensive medical The determination to mount a major research experiment in history was carried out in 1954. effort to eradicate polio arose in no small part from Well over a million young children participated, the involvement of President Franklin D. and the immediate direct costs were over 5 million Roosevelt, who' was struck down by polio when a dollars. The experiment was carried out to assess successful young politician. His determination to the effectiveness, if any, of the Salk vaccine as a overcome his paralytic handicap and the protection against paralysis or death from commitment to the fight against polio made by poliomyelitis. The study was elaborate in many Basil O'Connor, his former law partner, enabled a respects, most prominently in the use of placebo great deal of attention, effort, and money to be controls (children who were inoculated with simple expended on the care and rehabilitation of polio salt solution) assigned at random (that is, by a victims and—in the end, more importantly—on carefully applied chance process that gave each research into the causes and prevention of the volunteer an equal probability of getting vaccine or disease. salt solution) and subjected to a double-blind evaluation (that is, an arrangement under which During the course of this research, it was neither the children nor the physicians who discovered that polio is caused by a virus and that evaluated their subsequent state of health knew three main virus types are involved. -
Public Schools As Loci for Human Experimentation: Implications of Using Public Schools to House the Polio Vaccine Field Trial of 1954
Penn History Review Volume 23 Issue 2 Fall 2016 Article 4 December 2016 Public Schools as Loci for Human Experimentation: Implications of Using Public Schools to House the Polio Vaccine Field Trial of 1954 Will Schupmann University of Pennsylvania Follow this and additional works at: https://repository.upenn.edu/phr Recommended Citation Schupmann, Will (2016) "Public Schools as Loci for Human Experimentation: Implications of Using Public Schools to House the Polio Vaccine Field Trial of 1954," Penn History Review: Vol. 23 : Iss. 2 , Article 4. Available at: https://repository.upenn.edu/phr/vol23/iss2/4 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/phr/vol23/iss2/4 For more information, please contact [email protected]. Public Schools as Loci for Human Experimentation Public Schools as Loci for Human Experimentation: Implications of Using Public Schools to House the Polio Vaccine Field Trial of 1954 Will Schupmann In 1954, schoolchildren all across the United States par- ticipated in one of the largest medical experiments in history. Organized and carried out in public schools by the National Foundation for Infantile Paralysis, the feld trial tested the safety and effcacy of Jonas Salk’s vaccine for poliomyelitis (polio). The trial’s success was celebrated as a stunning and revolutionary tri- umph of science and medicine; just two years before, Americans had faced the largest epidemic of polio on record, permanently paralyzing twenty-one thousand individuals, but the trial’s suc- cess signaled an end to this era.1 The story of polio in the United States is well told; there is a great deal of scholarship on the history of polio, the experi- ence of living with the disease, the advent of Salk’s vaccine, and the success and legacy of the feld trial.2 This paper, however, adds to the scholarship by providing a critical perspective on the role of public schools in shaping public perceptions of and par- ticipation in the trial. -
Week 6 AIDS Part
Age of AIDS, Part Two. Scientific Breakthroughs National Institutes of Health, Bethesda, Maryland. >>NARRATOR: At the NIH, research scientists were trying to identify the mysterious agent that was causing the epidemic. >>DR. ANTHONY FAUCI: It was a period of evolving mystery. You couldn't see it, you look in the cells, you couldn't grow it, at least initially, and most everybody thought it was virus. >>NARRATOR: And many people thought that this man at the NIH, Dr. Robert Gallow, had a head start in the race to identify the virus. >>GEORGE SHAW, M.D. Ph.D.: I arrived in Bob Gallow's lab in 1983 and it was time of extraordinary excitement. >>NARRATOR: Four years earlier, Dr. Gallow had achieved a scientific breakthrough when he isolated a special virus, a retrovirus which caused leukemia. >>They were called HTLV 1 for human T-cell Leukemia Virus Type 1 and HTLV Type 2. Those viruses were actually prime candidates for the cause of AIDS. >>NARRATOR: Dr. Gallow and his team, convinced the AIDS virus was related to the HTLV, began probing the blood from an AIDS patient, using the same techniques he had used to discover the leukemia virus. >>DR. GALLOW: We were looking for HTLV-relatedness. We were looking for the AIDS virus to be related to the leukemia virus, a retrovirus, same family, but different. >>NARRATOR: But when Gallow cultured T-cells blood from the AIDS patients, he could find no markers of the HTLV. For Gallow, the idea that the AIDS virus could be anything except a variation of the HTLV seemed unthinkable.